Journal Information
Vol. 28. Issue 6.
Pages 296-302 (August - September 1992)
Share
Share
Download PDF
More article options
Vol. 28. Issue 6.
Pages 296-302 (August - September 1992)
Full text access
Enfisema pulmonar por déficit de alfa-1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento
Visits
6954
M. Miravitlles, R. Vidal, J. de Gracia
Servicio de Neumología. Hospital General Vall d’Hebron. Barcelona
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
C.B. Laurell, S.A. Eriksson.
The elelctrophoretic α-l-globulin pattern of serum in α-l-antitrypsin deficiency.
Scand J Clin Lab Invest, 15 (1963), pp. 132-140
[2.]
E. Eriksson.
Discovery of α-l-antitrypsin deficiency.
Lung, 168 (1990), pp. 523-529
[3.]
H.E. Schultze, K. Heide, H. Haupt.
Alpha-1-antitripsin aus Humanserum.
Klin Wochenschr, 40 (1962), pp. 427-429
[4.]
S. Eriksson.
Alpha 1 antitrypsin deficiency: lessons learned from the bedside to the gene and back again.
Chest, 95 (1989), pp. 181-189
[5.]
S. Eriksson.
Alpha-1-antitrypsin deficiency: Some personal experiences.
Schweiz Med Wschr, 114 (1984), pp. 893-894
[6.]
R.W. Carrell, J.O. Jeppson, C.B. Laurell, et al.
Structure and variation of human a-l-antitrypsin.
Nature, 298 (1982), pp. 329-333
[7.]
R.G. Crystal, M.L. Brantly, R.C. Hubbard, D.T. Curiel, D.J. States, M.D. Holmes.
The α-l-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy.
Chest, 95 (1989), pp. 196-208
[8.]
M. Brantly, T. Nukiwa, R.G. Crystal.
Molecular basis of α-lantitrypsin deficiency.
Am J Med, 84 (1988), pp. 13-31
[9.]
N. Kalsheker, K. Morgan.
The α-l-antitrypsin gene and chronic lung disease.
Thorax, 45 (1990), pp. 759-764
[10.]
A. Rodríguez Cuartera.
Alfa-1-antitripsina: Estudio general, bioquímico, genético y clínico.
Med Clin, 64 (1975), pp. 311-317
[11.]
R.M. Senior, H. Tegner, C. Kuhn, K. Ohlsson, B.C. Starcher, J.A. Pierce.
The induction of pulmonary emphysema with leukocyte elastase.
Am Rev Respir Dis, 116 (1977), pp. 469-475
[12.]
A. Janoff, B. Sloan, G. Weinbaum, et al.
Experimental emphysema induced with purified human neutfophil elastase: Tissue localization of the instilled protease.
Am Rev Respir Dis, 115 (1977), pp. 461-478
[13.]
R.W. Carell.
The molecular estructure and pathology of α-lantitrypsin.
Lung, 168 (1990), pp. 530-534
[14.]
D.C.S. Hutchinson.
The epidemiology of α-l-antitrypsin deficiency.
Lung, 168 (1990), pp. 535-542
[15.]
H.W. Goedde, L. Hirth, H.G. Benkmann, et al.
Population genetic studies of serum protein polymorphisms in four spanish populations: Part II.
Hum Hered, 23 (1973), pp. 235-246
[16.]
F. Ogushi, R.C. Hubbard, G.A. Fells, et al.
Evaluation of the S-type of α-l-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase.
Am Rev Respir Dis, 137 (1988), pp. 364-370
[17.]
D.W. Cox, H. Levison.
Emphysema of early onset associated with a complete deficiency of α-l-antitrypsin (null homozygotes).
Am Rev Respir Dis, 137 (1988), pp. 371-375
[18.]
R.I. Garver, J.F. Mornex, T. Nukiwa, et al.
Alpha-1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing α-1-antitrypsin genes.
N Engl J Med, 314 (1986), pp. 762-766
[19.]
J.A. Pierce, emphysema. Antitrypsin.
Perspective and prospects.
JAMA, 259 (1988), pp. 2.890-2.895
[20.]
J.H. Lewis, R.M. Iammarino, J.A. Spero, et al.
Antithrombin Pittsburgh: An α-1-antitrypsin variant causing hemorrhagic disease.
Blood, 51 (1978), pp. 129-137
[21.]
J.E. Gadek, E.R. Pacht.
The protease-antiprotease balance within the human lung: Implications for the pathogenesis of emphysema.
Lung, 168 (1990), pp. 552-564
[22.]
J.E. Gadek, G.A. Fells, R.L. Zimmerman, S.I. Rennard, R.G. Crystal.
Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.
J Clin Invest, 68 (1981), pp. 889-898
[23.]
S. Idell, U. Kucich, A. Fein, et al.
Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome.
Am Rev Respir Dis, 132 (1985), pp. 1.098-1.105
[24.]
M. Wewers.
Pathogenesis of emphysema. Asessment of basic Science concepts through clinical investigation.
Chest, 95 (1989), pp. 190-195
[25.]
C.G. Cochrane, R. Spragg, S.D. Revak.
Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid.
J Clin Invest, 71 (1983), pp. 754-761
[26.]
W.B. Davis, G.A. Fells, M.S. Chernick, P.A. diSant’Agnese, R.G. Crystal.
A role for neutrophils in the derangements of the bronchial wall characteristic of cystic fíbrosis.
Am Rev Respir Dis, 127 (1983), pp. 207A
[27.]
R.B. Fick, H.Y. Reynolds.
Pseudomonas respiratory infection in cystic fíbrosis: A possible defect in opsonic IgG antibody.
Bull Eur Physiopathol Respir, 19 (1983), pp. 151-161
[28.]
S. Suter, I. Chevallier.
Proteolytic inactivation of α-l-proteinase inhibitor in infected bronchial secretions from patients with cystic fíbrosis.
Eur Respir J, 4 (1991), pp. 40-49
[29.]
W.R. Abrams, A.M. Fein, V. Kucich, et al.
Proteinase inhibitory function in inflammatory lung disease.
Am Rev Respir Dis, 129 (1984), pp. 735-741
[30.]
J.I. Weitz, K.A. Crowley, S.L. Landman, B.I. Lipman, J. Yu.
Increased neutrophil elastase activity in cigarette smokers.
Ann Intern Med, 107 (1987), pp. 680-682
[31.]
R.T. Abboud, T. Fera, A. Richter, M.Z. Tabona, S. Johal.
Acute effect of smoking on the functional activity of α-l-protease inhibitor in bronchoalveolar lavage fluid.
Am Rev Respir Dis, 131 (1985), pp. 79-85
[32.]
S. Mangione, F. Kueppers, C. Puglia, L.W. Greenspon.
Erythrocytes prevent inactivation of α-1-antitrypsin by cigarette smoke.
Eur Respir J, 4 (1991), pp. 26-30
[33.]
D.J. Riley, J.S. Kerr.
Oxidant injury of the extracellular matrix: Potential role in the pathogenesis of pulmonary emphysema.
Lung, 163 (1985), pp. 1-13
[34.]
S.J. Weiss, S. Regiani.
Neutrophils degrade subendothelial matrices in the presence of α-1-proteinase inhibitor: Cooperative use of lysosomal proteinases and oxygen metabolites.
J Clin Invest, 73 (1984), pp. 1.297-1.303
[35.]
P. Laurent, A. Janoff, H.M. Kagan.
Cigarette smoke blocks cross-linking of elastin in vitro.
Am Rev Respir Dis, 127 (1983), pp. 189-192
[36.]
A. Janoff.
State of the art: elastases and emphysema.
Am Rev Respir Dis, 132 (1985), pp. 417-433
[37.]
F. Pelham, M. Wewers, R. Crystal, A.S. Buist, A. Janoff.
Urinary excretion of desmosine (elastin cross-links) in subjects with PiZZ α-1-antitrypsin deficiency, a phenotype associated with hereditary predisposition to pulmonary emphysema.
Am Rev Respir Dis, 132 (1985), pp. 821-823
[38.]
K.M. Moser, R.M. Smith, R.J. Spragg, G.M. Tisi.
Intravenous administration of α-1-proteinase inhibitor in patients of PiZ and PiM phenotype.
Am J Med, 84 (1988), pp. 70-74
[39.]
D.C.S. Hutchinson.
Natural history of a-l-protease inhibitor deficiency.
Am J Med, 84 (1988), pp. 3-12
[40.]
C. Larsson.
Natural history and life expectancy in severe α-1antitrypsin deficiency PiZ.
Acta Med Scand, 204 (1978), pp. 343-351
[41.]
E.D. Janus, N.T. Phillips, R.W. Carrell.
Smoking, lung function, and α-1-antitrypsin deficiency.
[42.]
M.C. Wu, S. Eriksson.
Lung function, smoking and survival in severe α-1-antitrypsin deficiency, PiZZ.
J Clin Epidemiol, 41 (1988), pp. 1.157-1.165
[43.]
E.K. Silverman, J.A. Pierce, M.A. Province, et al.
Variability of pulmonary function in α-1-antitrypsin deficiency: clinical correlates.
Ann Intern Med, 111 (1989), pp. 982-991
[44.]
M.J. Tobin, P.J.L. Cook, C.S. Hutchinson.
Alpha-1-antitrypsin deficiency: The clinical and physiological features in subjects homozygous for Pi type Z.
Br J Dis Chest, 77 (1983), pp. 4-27
[45.]
T. Evald, A. Dirksen, S. Keittelmann, K. Viskum, A. Kok-Jensen.
Decline in pulmonary function in patients with α-1-antitrypsin deficiency.
Lung, 168 (1990), pp. 579-585
[46.]
M.L. Brantly, L.D. Paul, B.H. Miller, R.T. Falk, M. Wu, R.G. Crystal.
Clinical features and history of the destructive lung disease associated with α-1-antitrypsin deficiency of adults with pulmonary symptoms.
Am Rev Respir Dis, 138 (1988), pp. 327-336
[47.]
J. Liberman, B. Winter, A. Sastre.
Alpha-1-antitrypsin Pi-types in 965 COPD patients.
Chest, 89 (1986), pp. 370-373
[48.]
D.W. Cox, V.H. Hoeppner, H. Levison.
Protease inhibitors in patients with chronic obstructive lung disease: the α-1-antitrypsin heterozygote controversy.
Am Rev Respir Dis, 113 (1976), pp. 601-606
[49.]
J. Lieberman.
A role for intermediate, heterozygous α-1antitrypsin deficiency in obstructive lung disease.
Chest, 98 (1990), pp. 522-523
[50.]
C. Mittman.
The PiMZ phenotype: Is it a significant risk factor for the development of chronic obstructive lung disease?.
Am Rev Respir Dis, 118 (1978), pp. 649-652
[51.]
S. Eriksson, J. Carlson, R. Velez.
Risk of cirrhosis and primary liver cancer in α-1-antitrypsin deficiency.
N Engl J Med, 314 (1986), pp. 736-739
[52.]
D.M. Parham, J.R. Paterson, A. Gunn, W. Guthrie.
Cholangiocarcinoma in two siblings with emphysema and α-1-antitrypsin deficiency.
Q J Med, 264 (1989), pp. 359-367
[53.]
S.S. Buist.
Alpha-1-antitrypsin deficiency, diagnosis, treatment and control: Identification of patients.
Lung, 168 (1990), pp. 543-551
[54.]
American Thoracic Society.
Guidelines for the approach to the patient with severe hereditary α-1-antitrypsin deficiency.
Am Rev Respir Dis, 140 (1989), pp. 1.494-1.497
[55.]
R. Cordero Torres, F.J. Saenz de Santamaria, F. Lozano Gutiérrez, A. Soria Monje, M. Perez Miranda.
Déficit de α-1-antitripsina asociado a enfermedad de Paget.
Rev Clin Esp, 171 (1983), pp. 437-438
[56.]
M.K. Fagerhol, H.E. Hauge.
Serum Pi type in patients with pulmonary diseases.
Acta Allergol, 24 (1969), pp. 107-114
[57.]
J.S. Hyde, P. Werner, C.M. Kumar, B.S. Moore.
Protease inhibitor variants in children and young adults with chronic asthma.
Ann Allergy, 43 (1979), pp. 8-13
[58.]
J.P. Michalski, C.C. McCombs, E. Scopelitis, J.J. Biundo, T.A. Medsger.
Alpha-1-antitrypsin phenotypes including M subtypes in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis.
Arthritis Rheum, 29 (1986), pp. 586-591
[59.]
D.W. Cox, O. Huber.
Rheumatoid arthritis and α-1-antitrypsin.
Lancet, 1 (1976), pp. 1.216-1.217
[60.]
R.C. Hubbard, S. Sellers, D. Czerski, L. Stephens, R.G. Crystal.
Biochemical efficacy and safety on monthly augmentation therapy for α-1-antitrypsin deficiency.
JAMA, 260 (1988), pp. 1.259-1.264
[61.]
G.L. Snider.
Pulmonary disease in α-1-antitrypsin deficiency.
Ann Intern Med, 111 (1989), pp. 957-958
[62.]
E.W. Schmidt, B. Rasche, W.T. Ulmer, et al.
Replacement therapy for α-l-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease.
Am J Med, 84 (1988), pp. 63-69
[63.]
N. Konietzko.
Alpha-1-antitrypsin substitution treatment or prevention of emphysema.
Lung, 168 (1990), pp. 592-598
[64.]
K. Viskum, A. Kok-Jensen.
Criteria for α-1-antitrypsin substitution.
Lung, 168 (1990), pp. 586-591
[65.]
R. Vidal, M. Miravitlles, X. De Gracia, B. Gallego, F. Morell.
Tratamiento sustitutivo del enfisema por déficit de α-1-antitripsina.
Med Clin, 96 (1991), pp. 180-182
[66.]
M.D. Wewers, M.A. Casolaro, R.G. Crystal.
Comparison of α-1antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the α-1-antitrypsin phenotype nuil-nuil before and during α-1-antitrypsin augmentation therapy.
Am Rev Respir Dis, 135 (1987), pp. 539-543
[67.]
M.D. Wewers, M.A. Casolaro, S.E. Sellers, et al.
Replacement therapy for α-1-antitrypsin deficiency associated with emphysema.
N Engl J Med, 316 (1987), pp. 1.055-1.062
[68.]
M.D. Wewers, M.L. Brantly, M.A. Casolaro, R.G. Crystal.
Evaluation of tamoxifen as a therapy to augment α-1-antitrypsin concentration in Z homozygous α-1-antitrypsin deficient individuals.
Am Rev Respir Dis, 135 (1987), pp. 401-404
[69.]
P.M. George, M.C.M. Vissers, J. Travis, C.C. Winterbourn, R.W. Carell.
A genetically engineered mutant of α-l-antitrypsin protects connective tissue from neutrophil damage and may be useful in lung disease.
Lancet, 2 (1984), pp. 1.426-1.428
[70.]
M. Courtney, A. Jallat, L.H. Tessier, A. Benavente, R.G. Crystal, J.P. LeCocq.
Synthesis in E. coli of a-l-antitrypsin variants with potential in the therapy of emphysema and thrombosis.
Nature, 313 (1985), pp. 149-151
[71.]
R.C. Hubbard, M.L. Brantly, S.E. Sellers, M.E. Mitchell, R.G. Crystal.
Anti-neutrophil-elastase defenses of the lower respiratory tract in α-l-antitrypsin deficiency directly augmented with an aerosol of a-l-antitrypsin.
Ann Intern Med, 111 (1989), pp. 206-212
[72.]
M.A. Casolaro, G.A. Fells, R.C. Hubbard, et al.
Augmentation of lung antineutrophil elastase capacity with recombinant human α-lantitrypsin.
J Appl Physiol, 63 (1987), pp. 2.015-2.023
[73.]
R.C. Hubbard, N.G. McElvaney, S.E. Sellers, J.T. Healy, D.B. Czerski, R.G. Crystal.
Recombinant DNA-produced α-l-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α-l-antitrypsin deficiency.
J Clin Invest, 84 (1989), pp. 1.349-1.354
[74.]
R.C. Hubbard, R.G. Crystal.
Strategies for aerosol therapy of α-l-antitrypsin deficiency by the aerosol route.
Lung, 168 (1990), pp. 565-578
[75.]
R.G. Crystal.
Reversible bronchoalveolar lavage.
Conferencia en «3rd International Conference in bronchoalveolar lavage». Viena 21-6-, (1991),
Copyright © 1992. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?